CTI BioPharma has one FDA-approved therapy, Vonjo, to treat a rare form of bone marrow cancer. The company is being bought at a 89% premium from its closing price on Tuesday. CTI will become a wholly ...
CTI has acquired Texolve Digital of Oakmont, PA. Adding Texolve’s team, which provides broadcast engineering and integration at the highest level, will expand the broadcast media division’s ability to ...
Intel 471 has launched a free Cyber Threat Intelligence Maturity Pulse Check to help organizations quickly assess the ...
SACRAMENTO, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Composite Technology International (CTI), a leader in the manufacturing of innovative building products, is pleased to announce the appointment of ...
CTI Biopharma has something many biotech companies aspire to achieve—revenue. Sales of its approved cancer drug are growing, but commercialization comes with costs as does development of the molecule ...
On March 1, 2022, the FDA approved Vonjo to treat patients with myelofibrosis, a rare bone marrow disorder. During the clinical trial that led to its approval, 29% of patients treated with Vonjo ...
Vonjo will carry a wholesale acquisition cost of $19,500 a month, CTI executives said on a call with investors Tuesday. (Pixabay) It’s been a long and tortuous path to approval for CTI BioPharma’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results